Nucleoside analogues for the treatment of parasitic infections

The invention relates to the tubercin analogues showing potential against either T.brucei (sleeping sickness) or T.cruzi (Chagas disease). Our invention beholds the discovery of two series of (deaza)purine analogues that show very potent inhibition of parasite growth in vitro. In a proof-of-concept animal model the compounds showed non-inferior efficacy with respect to the reference drug, suramin (which is clinically used for stage I Human African Trypanosomiasis (HAT)). Additionally, as other parasites might also be sensible to some of these analogues, a multi-targeting derivative could be identified. We already identified one derivative which shows potent in vitro potential against both T.brucei & T.cruzi.

Octrooi-publicatienummer: WO2019076633

Jaar aanvraag: 2019

Jaar toekenning: 2020

Jaar van publicatie: 2019

Status: Aangevraagd

Technologiedomeinen: Farmaceutische producten

Gevalideerd voor IOF-sleutel: Ja

Toegewezen aan: Associatie Universiteit & Hogescholen Antwerpen, Associatie Universiteit Gent